ABOUT US
STAATZ – YOUR PARTNER FOR BUSINESS DEVELOPMENT & MARKET ACCESS
We are matching partners, products and technologies within the healthcare industry, building value for our pharma and biotech clients as well as their institutional and private investors.
With an in-depth understanding of different stakeholders’ perspective, we provide strategic guidance around value and evidence of your product to match payer expectations for successful market access across Europe.
OUR MISSION
We are matching partners, products and technologies within the healthcare industry building value for corporate and private investors.
Our transactions, which span all development stages and a broad range of indications, have exceeded a deal value of more than USD 4 BN up to date.
We have a sound network in the pharmaceutical, biotechnology and the Life Science financing community, which allows for access to top level decision makers in BD and R&D departments of target companies.
Together with our extensive biotech and pharma industry experience as well as our determination for success this led us to successfully complete a significant number of a variety of transactions with excellent financial returns for our clients.
MARKET ACCESS
We tailor the value of your product to resonate with payers and enable patient access.
We provide strategic guidance around evidence creation to match payer expectations across the product lifecycle.
We support the process to commercialization from early stages, through to negotiations with pricing and reimbursement authorities.
Our track record includes strategic insights and support, launch sequence advice, creation of compelling value propositions, generation of value dossiers, HTA landscape assessments, and the preparation and execution of payer and clinician advisory board sessions.
Drug Development / Regulatory
By following this link you are leaving the STAATZ Business and Development website
Executive Masterclass: Europe Launch Options
September 14, 2026 - Boston
September 16, 2026 - San Francisco
World Orphan Drug Congress Europe 2026
October 26 - 28, 2026 - Amsterdam
Bio Europe
November 9 - 11, 2026 - Cologne
STAATZ CONSULTING advised Womed on its strategic partnership with Karl Storz
February 12th, 2026
Partnership brings Womed Leaf® to the Japanese market
January 28th, 2026
Womed partnered Womed Leaf® in Brazil to Bioargo
July 7th, 2025
Kebomed Europe secures license to distribute Womed Leaf®
April 9th, 2025
Transaction Advisor to Allecra Therapeutics GmbH
June 24, 2024